Boston Scientific Corp. won the latest round in its long-running patent war with Johnson & Johnson when a federal judge declared invalid a quartet of J&J subsidiary Cordis Corp.’s patents for drug-eluting stents.
The patents in question are at the heart of complicated legal wrangling involving the Natick, Mass.-based medical device giant, its new Brunswick, N.J.-based rival, Abbott, and Wyeth. The dispute centers around Boston Scientific’s Promus stent, a private-label version of Abbott’s Xience V stent, and the Cordis Cypher.
BSX asked Judge Susan Robinson of the U.S. District Court for Delaware to rule the four patents invalid on various grounds; JNJ wanted Robinson to declare infringement of a single claim contained in one of the patents, according to court documents. Robinson ruled in favor of Boston Scientific’s claim that J&J’s patent covering the sirolimus (also called rapamycin) used in Cordis‘s Cypher stent doesn’t cover the everolimus drug BSX uses in the Promus device. Everolimus is made by modifying the sirolimus molecule at a single location.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Robinson also found that the fourth patent wasn’t specific enough in describing exactly which drug formulations it covered to be valid, because the patent didn’t include a written description of at least one example of such a formulation.
Her decision, which means a jury trial scheduled for Feb. 9 will not happen, is not the last word in the stents war between Boston Scientific and Johnson & Johnson.
“Boston Scientific will continue to vigorously defend against any charges of infringement. We continue to attempt to resolve remaining outstanding matters with Johnson & Johnson.,” BSX CEO Ray Elliott said in a prepared statement.
Boston Scientific agreed to pay Cordis $716 million in September 2009 to settle 14 stent patent infringement suits. The settled cases, involving lawsuits in U.S., Canadian, Belgian, German, French and Italian courts, include the so-called Palmaz-NIR suit, involving a patent by the radiologist who invented stents, Julio Palmaz.
BioLabs Pegasus Park Cultivates Life Science Ecosystem
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The estimated settlement cost in that case would make up most of the $716 million nut to settle it and the other 13 suits.
Johnson & Johnson owns that patent and in 2000 won a lawsuit alleging that an early BoSci stent, the NIR, infringed the technology, according to the Wall Street Journal (paid). Boston Scientific appealed, but told investors in 2008 that it expected that case to cost at least $703 million.
